Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine + CoronaVac COVID-19 vaccine + ChAdOx1 nCoV-19 Covid-19 Vaccine + Ad26.COV2.S COVID-19 Vaccine
Pre-clinicalCompleted 0 watching 0 views this week๐ค Quiet
22
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Covid19
Conditions
Covid19
Trial Timeline
Nov 3, 2021 โ Jul 20, 2023
NCT ID
NCT05052307About Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine + CoronaVac COVID-19 vaccine + ChAdOx1 nCoV-19 Covid-19 Vaccine + Ad26.COV2.S COVID-19 Vaccine
Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine + CoronaVac COVID-19 vaccine + ChAdOx1 nCoV-19 Covid-19 Vaccine + Ad26.COV2.S COVID-19 Vaccine is a pre-clinical stage product being developed by Pfizer for Covid19. The current trial status is completed. This product is registered under clinical trial identifier NCT05052307. Target conditions include Covid19.
Hype Score Breakdown
Clinical
5
Activity
2
Company
9
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05052307 | Pre-clinical | Completed |
Competing Products
20 competing products in Covid19